Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD)
- PMID: 23717629
- PMCID: PMC3661525
- DOI: 10.1371/journal.pone.0064558
Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD)
Abstract
Patients with CKD have abnormal vascular remodeling that is a risk factor for cardiovascular disease. MicroRNAs (miRNAs) control mRNA expression intracellularly and are secreted into the circulation; three miRNAs (miR-125b, miR-145 and miR-155) are known to alter vascular smooth muscle cell (VSMC) proliferation and differentiation. We measured these vascular miRNAs in blood from 90 patients with CKD and found decreased circulating levels with progressive loss of eGFR by multivariate analyses. Expression of these vascular miRNAs miR-125b, miR-145, and miR-155 was decreased in the thoracic aorta in CKD rats compared to normal rats, with concordant changes in target genes of RUNX2, angiotensin II type I receptor (AT1R), and myocardin. Furthermore, the expression of miR-155 was negatively correlated with the quantity of calcification in the aorta, a process known to be preceded by vascular de-differentiation in these animals. We then examined the mechanisms of miRNA regulation in primary VSMC and found decreased expression of miR-125b, 145, and 155 in VSMC from rats with CKD compared to normal littermates but no alteration in DROSHA or DICER, indicating that the low levels of expression is not due to altered intracellular processing. Finally, overexpression of miR-155 in VSMC from CKD rats inhibited AT1R expression and decreased cellular proliferation supporting a direct effect of miR-155 on VSMC. In conclusion, we have found ex vivo and in vitro evidence for decreased expression of these vascular miRNA in CKD, suggesting that alterations in miRNAs may lead to the synthetic state of VSMC found in CKD. The decreased levels in the circulation may reflect decreased vascular release but more studies are needed to confirm this relationship.
Conflict of interest statement
Figures
Similar articles
-
Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease.Biochim Biophys Acta. 2014 Jan;1842(1):88-98. doi: 10.1016/j.bbadis.2013.10.005. Epub 2013 Oct 16. Biochim Biophys Acta. 2014. PMID: 24140891
-
Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification.Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1402-1414. doi: 10.1161/ATVBAHA.117.309566. Epub 2017 May 18. Arterioscler Thromb Vasc Biol. 2017. PMID: 28522697
-
Circulating microRNAs (miR-126, miR-197, and miR-223) are associated with chronic kidney disease among elderly survivors of the Great East Japan Earthquake.BMC Nephrol. 2019 Dec 21;20(1):474. doi: 10.1186/s12882-019-1651-0. BMC Nephrol. 2019. PMID: 31864304 Free PMC article.
-
MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease.Cell Cycle. 2009 Nov 1;8(21):3469-73. doi: 10.4161/cc.8.21.9837. Epub 2009 Nov 17. Cell Cycle. 2009. PMID: 19829088 Free PMC article. Review.
-
Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury?Physiol Genomics. 2011 May 1;43(10):529-33. doi: 10.1152/physiolgenomics.00146.2010. Epub 2010 Sep 14. Physiol Genomics. 2011. PMID: 20841497 Free PMC article. Review.
Cited by
-
Evaluation of MicroRNA 145 and MicroRNA 155 as Markers of Cardiovascular Risk in Chronic Kidney Disease.Cureus. 2024 Aug 9;16(8):e66494. doi: 10.7759/cureus.66494. eCollection 2024 Aug. Cureus. 2024. PMID: 39246913 Free PMC article.
-
MicroRNA193a: An Emerging Mediator of Glomerular Diseases.Biomolecules. 2023 Dec 4;13(12):1743. doi: 10.3390/biom13121743. Biomolecules. 2023. PMID: 38136614 Free PMC article. Review.
-
Advances in the study of miRNAs in chronic kidney disease with cardiovascular complications.Front Physiol. 2023 Nov 23;14:1283597. doi: 10.3389/fphys.2023.1283597. eCollection 2023. Front Physiol. 2023. PMID: 38074330 Free PMC article. Review.
-
Uremic Toxin-Induced Exosome-like Extracellular Vesicles Contain Enhanced Levels of Sulfated Glycosaminoglycans which Facilitate the Interaction with Very Small Superparamagnetic Iron Oxide Particles.Int J Mol Sci. 2023 Sep 18;24(18):14253. doi: 10.3390/ijms241814253. Int J Mol Sci. 2023. PMID: 37762555 Free PMC article.
-
Investigation of XPD, miR-145 and miR-770 expression in patients with end-stage renal disease.Mol Biol Rep. 2023 Aug;50(8):6843-6850. doi: 10.1007/s11033-023-08608-w. Epub 2023 Jul 1. Mol Biol Rep. 2023. PMID: 37392287
References
-
- Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297. - PubMed
-
- Lorenzen JM, Haller H, Thum T (2011) MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286–294. - PubMed
-
- van Rooij E (2012) Introduction to the series on microRNAs in the cardiovascular system. Circ Res 110: 481–482. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous